drugset / Trial / NCT00003613

O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

NCT00003613

Phase 1 Terminated 20 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of carmustine given together with O(6)-benzylguanine in treating patients with stage I or stage II cutaneous T-cell lymphoma that has not responded to previous treatment. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells

Timeline

Start
1999-04
Primary completion
2006-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject O6-benzylguanine Small molecule 120 mg/m2 Intravenous
Subject carmustine Small molecule 10 mg Topical
Subject carmustine Small molecule 20 mg Topical
Subject carmustine Small molecule 30 mg Topical
Subject carmustine Small molecule 40 mg Topical